Wednesday, February 10, 2010, 1:24PM AEST - The Australian Stockmarket closes in 2 hours and 41 minutes.
To create a watchlist or portfolio of shares, Register

Aastrom Biosciences, Inc. (ASTM)

7:59AM AEST: 0.1819 USD  Down 0.0291 (13.79%)  
 MORE ON ASTM 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Aastrom Biosciences, Inc. (NCM:ASTM) Delayed quote dataEdit
Last Trade:0.1819 USD
Trade Time: 7:59AM AEST
Change:Down 0.0291 (13.79%)
Prev Close:0.211
Open:0.185
Bid:0.16 x 4000
Ask:N/A
1y Target Est:0.50
Day's Range:0.165 - 0.19
52wk Range:0.17 - 0.63
Volume:15,084,948
Avg Vol (3m):2,913,400
Market Cap:31.65M
P/E (ttm):N/A
EPS (ttm):-0.105
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ASTM to Portfolio   Download Data

 HEADLINES 
AASTROM BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia
EDGAR Online (Wed 1:09AM)
InPlay: Aastrom Biosciences announces one-for-eight reverse stock split
Briefing.com (Wed 12:31AM)
Aastrom Announces One-for-Eight Reverse Stock Split
GlobeNewswire (Wed 12:30AM)
AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi
EDGAR Online (Thu, Jan 28)
Q+A-Skin cells transformed directly to nerve in study
at Reuters (Thu, Jan 28)
Biotech Stock Alert for Aastrom Biosciences Inc. Issued by InvestorSoup
GlobeNewswire (Mon, Jan 25)
Aastrom Biosciences Announces Closing of Unit Offering
GlobeNewswire (Fri, Jan 22)
Skymark Research Initiates Independent Research Coverage On Aastrom Biosciences, Inc.
GlobeNewswire (Wed, Jan 20)
AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Sat, Jan 16)
Aastrom, Broadwind Energy: Late Day Volume Plays
at TheStreet.com (Sat, Jan 16)
More Headlines for ASTM...

 ANALYST 
EPS Est (next year) (Jun-10) :N/A
EPS Est (in 2 years) (Jun-11) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aastrom Biosciences, Inc. engages in developing autologous cell products for the treatment of severe, chronic, and cardiovascular diseases. The company's proprietary tissue repair cell (TRC) technology expands the numbers of stem and early pr...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices